Physician profile
Thomas Deblasio
NPI 1285790782
$34,604.04
in general payments reported to CMS, 2019-2025
57 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,825 · 2020: $5,261 · 2021: $6,706 · 2022: $4,915 · 2023: $4,379 · 2024: $2,716 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,897.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,657.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $4,493.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,301.80 | 2019-2024 | Xifaxan |
| Amgen INC. | $2,253.89 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $2,019.52 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $1,864.50 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,817.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,605.75 | 2019-2025 | |
| Lilly USA, LLC | $1,452.40 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $1,041.99 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $1,027.56 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $954.18 | 2019-2023 | Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $949.40 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $892.90 | 2019-2025 | Trintellix |
| Abbott Laboratories | $775.59 | 2020-2025 | Freestyle Libre 3, Proclaim |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Deblasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.